The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

The Complexity of the PARP Inhibitor Landscape in Ovarian Cancer

Douglas A. Levine, MD
Published Online:7:05 PM, Fri June 16, 2017

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, and director, Divison of Gynecologic Oncology, NYU Langone Medical Center, discusses the impact of PARP inhibitors on the landscape of ovarian cancer.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.